IntegraGen : Reports 2015 Revenues

Strong cash position: € 5.0 million as of December 31, 2015 compared to € 4.0 million on June 30, 2015

·Robust development of activity on genomic platforms hosted by Gustave Roussy and Institut

Pasteur with operations expanded to include additional hospitals

·Lower revenue for genomic services business primarily due to pricing pressures associated with research services

EVRY, France (January 14, 2016) - IntegraGen (FR0010908723 - ALINT - PEA Eligible SMEs), which specializes in decoding the human genome and delivers relevant and easily interpretable analyzes for academic and private laboratories, today announced its full year revenues for 2015. After a stable first half (+ 1%), revenues declined in the second half of the year resulting in a 7% decline in revenue for full year 2015 compared to 2014. While the project volume increased versus 2014, pricing pressure, especially for research services, weighed significantly on the company's total revenues. Furthermore, sales for the second half of 2014 were particularly high, with a growth of 26% compared to H2 2013, with an exceptional level of activity in November and December that was not matched in 2015.

The company reported dynamic growth in its "clinical research" segment with a strong increase in sample volumes for the platform hosted at Gustave Roussy, which carries out sequencing studies for clinical research project, and the establishment of a sequencing platform for microbiology studies at the Pasteur Institute during the first half of 2015. Sequencing revenue for clinical research-related activities represented 25% of the company's total sales in 2015. Finally, annual order intake increased 23% compared to 2014 allowing to anticipate a stronger activity in 2016.

Cash burn was reduced resulting in a cash position of €5.0m at end December 2015 versus € 4.0m as of June 30, 2014, reflecting the financial strength of the company. This situation is due in particular to IntegraGen's cost control, through the exercise of options related to PACEO established with Société Générale (€ 0.7m), and by a BPI payment from France associated with the last tranche of the repayable advance "BIOMOS" (€ 0.4m) on the project to develop biomarkers in oncology.